In this issue:
Silent progression in disease activity-free relapsing MS
Rituximab treatment and disability progression in SPMS
Changes in the risk of reaching MS disability milestones in recent decades
Safety and efficacy of aHSCT following natalizumab discontinuation in aggressive MS
Factors associated with long-term outcome of benign MS
Ocrelizumab efficacy in subgroups of patients with RRMS
Discontinuation of DMT in MS patients over age 60
Contribution of secondhand tobacco smoke to paediatric MS risk
Meta-analysis: ocrelizumab vs other treatments for relapsing MS
Safety of cladribine for MS
Please login below to download this issue (PDF)